These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy. Farwell MD; Clark AS; Mankoff DA JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243 [No Abstract] [Full Text] [Related]
3. Maurie Markman on the Groundbreaking TAPUR Trial. Markman M Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751 [No Abstract] [Full Text] [Related]
4. Predictive pathology in routine diagnostics of solid tumors. Lassmann S; Werner M Histol Histopathol; 2012 Mar; 27(3):289-96. PubMed ID: 22237706 [TBL] [Abstract][Full Text] [Related]
5. Oncology biomarkers--second annual GTCbio conference. Biomarkers for disease detection and therapeutics monitoring. 19-20 January 2009, Miami, FL, USA. Scholler N IDrugs; 2009 Apr; 12(4):207-10. PubMed ID: 19350459 [No Abstract] [Full Text] [Related]
7. Quantum dots for tumor-targeted drug delivery and cell imaging. Misra RD Nanomedicine (Lond); 2008 Jun; 3(3):271-4. PubMed ID: 18510421 [No Abstract] [Full Text] [Related]
8. Personalized Medicine: Genomics Trials in Oncology. Hayes DF; Schott AF Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667 [TBL] [Abstract][Full Text] [Related]
10. Nanotechnology grows into billion-dollar enterprise. Vastag B J Natl Cancer Inst; 2004 Nov; 96(21):1566-7. PubMed ID: 15523079 [No Abstract] [Full Text] [Related]
11. Nanoparticle and targeted systems for cancer therapy. Brannon-Peppas L; Blanchette JO Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294 [TBL] [Abstract][Full Text] [Related]
12. Achieving the goals of effective, safe, and individualized cancer care. Roberts SA; Karnes EK; Allen JD; Benner JS; Sigal EV; McClellan M Clin Cancer Res; 2011 Nov; 17(21):6632-3. PubMed ID: 22046023 [No Abstract] [Full Text] [Related]
13. An accelerated pathway for targeted cancer therapies. McClellan M; Benner J; Schilsky R; Epstein D; Woosley R; Friend S; Sidransky D; Geoghegan C; Kessler D Nat Rev Drug Discov; 2011 Feb; 10(2):79-80. PubMed ID: 21283090 [TBL] [Abstract][Full Text] [Related]
14. Editorial (Thematic Issue: The Predictive Pathology in the Target Therapy Era). Franco R; Cantile M Curr Drug Targets; 2017; 18(1):2-3. PubMed ID: 27991404 [No Abstract] [Full Text] [Related]
15. SRC as a potential therapeutic target in solid tumor oncology. Gallick GE Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218 [No Abstract] [Full Text] [Related]
16. Deceptive argumentation against diagnostic microdosing of anticancer drugs. Theile D; Mikus G Int J Cancer; 2014 Oct; 135(7):1753-4. PubMed ID: 24615734 [No Abstract] [Full Text] [Related]
17. [The breakthrough of personalized medicine, new hopes and new challenges]. Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365 [TBL] [Abstract][Full Text] [Related]
18. Challenges ahead for companion diagnostics. Schmidt C J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588 [No Abstract] [Full Text] [Related]
19. Steps forward for cancer precision medicine. Salgado R; Moore H; Martens JWM; Lively T; Malik S; McDermott U; Michiels S; Moscow JA; Tejpar S; McKee T; Lacombe D; Nat Rev Drug Discov; 2018 Jan; 17(1):1-2. PubMed ID: 29170471 [TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers for cancer therapy with PARP inhibitors. Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]